Last reviewed · How we verify

NCT03604536

Individualization Treatment Through a Self-managed Web-based Solution in Ulcerative Colitis

Terminated Last updated 9 March 2022
What this trial tests

trial in Inflammatory Bowel Diseases in 1 participant. Terminated before completion.

Timeline
2 December 2019
Primary endpoint
31 August 2021
31 December 2021

Quick facts

Lead sponsorNordsjaellands Hospital
StatusTerminated
Study typeOBSERVATIONAL
Enrollment1
Start date2 December 2019
Primary completion31 August 2021
Estimated completion31 December 2021
Sites1 location across Denmark

Conditions studied

Sponsor

Nordsjaellands Hospital

Who can join

Adults 18 to 75, any sex, with Inflammatory Bowel Diseases or Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the effect of individualized monotherapy with Mesalazine (Pentasa Sachet ®) on time to remission in patients with mild to moderate UC in an eHealth setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

Other Nordsjaellands Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03604536.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing